WZWei Zhang

Wei Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wei Zhang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Dongmin Zhao

    Key Laboratory for Candidate Drug Design and Screening Based on Chemical Biology, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China

    1 shared publication
  • Guodong Liang

    College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China

    1 shared publication
  • Jiali Zhao

    Key Laboratory for Candidate medicine Design and Screening Based on Chemical Biology, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China

    1 shared publication
  • Jianping Chen

    College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China

    1 shared publication
  • Jiaqi Xu

    Key Laboratory for Candidate medicine Design and Screening Based on Chemical Biology, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China

    1 shared publication
  • Qilu Yan

    Key Laboratory for Candidate medicine Design and Screening Based on Chemical Biology, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China

    1 shared publication

Latest Publications

  • Open Access

    Design of Artificial Peptide Against HIV-1 Based on the Heptad-Repeat Rules and Membrane-Anchor Strategies

    by Jiali Zhao, Yan Zhao, Xiao Qi, Xiaojie Lv, Yanbai Tang, Wei Zhang, Qingge Dai, Jiaqi Xu, Dongmin Zhao, Qilu Yan, et al.

    Objective: The six-helix bundle (6-HB) is critical for HIV-1 membrane fusion. To disrupt this process, peptide inhibitors have been meticulously designed to target interactions within the 6-HB regions, thereby blocking membrane fusion and exerting inhibitory effects. Current peptide inhibitors like Enfuvirtide suffer from drug resistance and short in vivo half-life. This study aims to design novel anti-HIV-1 peptides by integrating heptad-repeat rules and membrane-anchor strategies. Methods: Artificial peptides were designed using HR rules from the HIV-1 gp41 6-HB motif and membrane-anchor modifications. Results: EK35S-Palm has emerged as a highly promising candidate for HIV-1 inhibition, exhibiting robust binding affinity to the target and effectively impeding the 6-HB spontaneous formation. Discussion: HR-based design avoids viral sequence homology, and membrane anchoring enhances local agent concentration, improving pharmacokinetics. The HR binding and membrane stabilization of EK35S-Palm provide synergistic inhibition. Conclusions: Integrating HR structural design with membrane-anchor strategies yields potent HIV-1 fusion inhibitors. EK35S-Palm demonstrates superior efficacy and stability over current therapies. These approaches hold great potential for overcoming the current therapy limitations and advancing the more effective and durable HIV-1 fusion inhibitors.